论文标题
Omicron BA.2（B.1.1.529.2）：成为下一个主导变体的高潜力
Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant
论文作者
论文摘要
严重急性呼吸综合征冠状病毒2（SARS-COV-2）的OMICRON变体已迅速取代了Delta变体，因为自然选择，它是一种主要的SARS-COV-2变体，它具有更高的感染性和较强的疫苗突破能力，从而有利于这种变体。 Omicron具有三个谱系或子变量，BA.1（B.1.1.529.1），BA.2（B.1.1.529.2）和BA.3（B.1.1.529.3）。其中，BA.1是当前盛行的子变量。 BA.2与BA.1共享32个突变，但具有28个不同的突变。 BA.3与BA.1和BA.2共享其大部分突变。 BA.2被发现能够令人震惊地恢复最初被Omicron BA.1感染的患者。一个重要的问题是BA.2或BA.3是否将成为新的主导“关注的变体”。目前，尚未报告有关BA.2和BA.3的实验数据。我们构建了一种新型的基于代数拓扑的深度学习模型，该模型训练了数以万计的突变和深突变数据，以系统地评估BA.2和BA.3的感染性，疫苗突破能力以及抗体抗性。我们对所有主要变体的比较分析，即Alpha，Beta，Gamma，Delta，Lambda，Mu，Ba.1，ba.2和Ba.3，揭示了BA.2分别是BA.1和Delta的传染性。它的功能分别比BA.1和三角洲的功能分别具有30％和17倍，以逃避当前的疫苗。因此，我们预测Omicron BA.2正处于成为下一个主导变体的道路上。我们预测，除了Omicron Ba.1，BA.2也将严重妥协大多数现有的mab，除了glaxosmithkline开发的Sotrovimab外。
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly replaced the Delta variant as a dominating SARS-CoV-2 variant because of natural selection, which favors the variant with higher infectivity and stronger vaccine breakthrough ability. Omicron has three lineages or subvariants, BA.1 (B.1.1.529.1), BA.2 (B.1.1.529.2), and BA.3 (B.1.1.529.3). Among them, BA.1 is the currently prevailing subvariant. BA.2 shares 32 mutations with BA.1 but has 28 distinct ones. BA.3 shares most of its mutations with BA.1 and BA.2 except for one. BA.2 is found to be able to alarmingly reinfect patients originally infected by Omicron BA.1. An important question is whether BA.2 or BA.3 will become a new dominating "variant of concern". Currently, no experimental data has been reported about BA.2 and BA.3. We construct a novel algebraic topology-based deep learning model trained with tens of thousands of mutational and deep mutational data to systematically evaluate BA.2's and BA.3's infectivity, vaccine breakthrough capability, and antibody resistance. Our comparative analysis of all main variants namely, Alpha, Beta, Gamma, Delta, Lambda, Mu, BA.1, BA.2, and BA.3, unveils that BA.2 is about 1.5 and 4.2 times as contagious as BA.1 and Delta, respectively. It is also 30% and 17-fold more capable than BA.1 and Delta, respectively, to escape current vaccines. Therefore, we project that Omicron BA.2 is on its path to becoming the next dominating variant. We forecast that like Omicron BA.1, BA.2 will also seriously compromise most existing mAbs, except for sotrovimab developed by GlaxoSmithKline.
